Skip to content

Changes in Corneal Endothelial Cell Density After Transscleral ab Interno Glaucoma Gel Stent Implantation

Changes in Corneal Endothelial Cell Density After Transscleral ab Interno Glaucoma Gel Stent Implantation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04547036
Enrollment
129
Registered
2020-09-14
Start date
2020-01-30
Completion date
2021-04-30
Last updated
2021-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Cell Loss, Corneal, Glaucoma

Brief summary

The objective of this study is to evaluate the change of endothelial cell count after XEN45 in patients with or without cataract operation.

Detailed description

STUDY OBJECTIVE Corneal endothelial cell loss is a known sequela of glaucoma tube shunt implantation. Big tube shunts show a decrease of endothelial cell count postoperatively (-11.5% after Ahmed glaucoma valves and -12.4% after Molteno shunt 2 years postoperatively). The objective of this study is to evaluate the change of endothelial cell count after XEN45 in patients with or without cataract operation. PATIENT POPULATION In 140 open angle eyes central endothelial cell counts were recorded preoperatively, before the XEN45 implantation was performed in Dept. Ophthalmology at Paracelsus Medical University Salzburg. XEN45s were already performed in the year 2013-2017 (so up to 5 years) in open angle glaucoma eyes in combination with or without cataract operation. In these eyes central endothelial cell count and central corneal thickness was measured preoperatively and documented in patients records. STUDY DESIGN A prospective, observational, monocentric trial to evaluate the course of endothelial cell density after the XEN implant. The study will take place in the Dept. Ophthalmology at Paracelsus Medical University Salzburg/SALK. Up to 140 consecutive patients with preoperatively recorded endothelial cell counts will be summoned to a consecutive endothelial cell count record and measurement of central corneal thickness postoperatively. Informed consents will be obtained from patients, who are interested in participating in the study. Patients will be assessed for endothelial cell density and the position of the XEN45 measured by anterior segment optical coherence tomography. The distance of the XEN45 to cornea, the angle of the tube, and the tube length in the anterior chamber will be recorded with anterior segment optical coherence tomography. Endothelial cell density will be measured on 3 positions: central, superior-nasal (location of XEN45 implantation), infero-temporal (far away for the XEN45 implant). OUTCOME PARAMETERS The primary endpoint is the change of central endothelial cell density compared to preoperative data. Secondary objectives are the differences of supero-nasal and infero-temporal endothelial cell density compared to the central endothelial cell density, and pachymetry compared to preoperative data. EXAMINATION SCHEDULE Subjects will undergo study visits at the following times: preoperative data (2013-2017) out of patient records, postoperative visit in the year 2018-2020 (1-7 years post XEN45 implantation). CLINICAL PARAMETERS The following clinical assessments will be performed at the postoperative examination: 1. Endothelial cell count on different locations of the study eye 2. Central corneal thickness 3. Anterior segment optical coherence tomography (to determine the position of the XEN45) 4. Slit lamp examination of the cornea, anterior segment including gonioscopy (to determine the position of the XEN45), and dilated fundus examination 5. Best corrected visual acuity 6. Measurement of IOP 7. Number and frequency of ocular (glaucoma) medications 8. Ocular symptoms and assessment of complications (especially symptoms, which may be a hint for loss of endothelial cell count) 9. Secondary surgical procedures (if applicable including needlings, lasers, cataract operation, bleb revisions, keratoplasty, secondary IOP lowering procedures, other operations)

Interventions

DEVICEXEN45

Up to 140 consecutive patients with preoperatively recorded endothelial cell counts will be summoned to a consecutive endothelial cell count record and measurement of central corneal thickness postoperatively.

Sponsors

Paracelsus Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Open Angle Glaucoma 2. History past XEN45 implantation with or without combined cataract procedure 3. Available preoperative endothelial cell count data not older than 1 year before XEN operation without any operation between the day of data record and XEN45 operation. 4. Age 18 years or older and of legal age of consent 5. Signed written informed consent 6. Availability, willingness, and sufficient cognitive awareness to comply with examination procedures

Exclusion criteria

1\. Patients with secondary IOP lowering procedures (excluding SLT, needlings, bleb revisions, YAG lasers, Argon lasers) after XEN implantation will be excluded from analysis, because the secondary IOP lowering procedures may influence endothelial cell count itself. Cataract operations without complications are no

Design outcomes

Primary

MeasureTime frameDescription
Endothelial Cell Count Changebaseline compared to 1-5 years postoperativeThe primary endpoint is the change of central endothelial cell density compared to preoperative data.

Countries

Austria

Participant flow

Participants by arm

ArmCount
XEN45 Implantation With and Without Combined Cataract Surgery
Eyes with a history past XEN45 implantation with and without combined cataract surgery and preoperatively recorded baseline central endothelial cell counts were included for the postoperative examination.
129
XEN45 Implantation With and Without Combined Cataract Surgery
Eyes with a history past XEN45 implantation with and without combined cataract surgery and preoperatively recorded baseline central endothelial cell counts were included for the postoperative examination.
155
Total284

Baseline characteristics

CharacteristicXEN45 Implantation With and Without Combined Cataract Surgery
Age, Continuous75.4 years
STANDARD_DEVIATION 10.3
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Eyes
Ethnicity (NIH/OMB)
Not Hispanic or Latino
155 Eyes
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Eyes
Race (NIH/OMB)
American Indian or Alaska Native
0 Eyes
Race (NIH/OMB)
Asian
0 Eyes
Race (NIH/OMB)
Black or African American
0 Eyes
Race (NIH/OMB)
More than one race
0 Eyes
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Eyes
Race (NIH/OMB)
Unknown or Not Reported
0 Eyes
Race (NIH/OMB)
White
155 Eyes
Region of Enrollment
Austria
155 Eyes
Sex: Female, Male
Female
66 Eyes
Sex: Female, Male
Male
89 Eyes

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 129
other
Total, other adverse events
37 / 129
serious
Total, serious adverse events
0 / 129

Outcome results

Primary

Endothelial Cell Count Change

The primary endpoint is the change of central endothelial cell density compared to preoperative data.

Time frame: baseline compared to 1-5 years postoperative

ArmMeasureGroupValue (MEDIAN)
Endothelial Cell Count MeasurmentEndothelial Cell Count Change1 year2 % change compared to baseline
Endothelial Cell Count MeasurmentEndothelial Cell Count Change2 years-1 % change compared to baseline
Endothelial Cell Count MeasurmentEndothelial Cell Count Change3 years0 % change compared to baseline
Endothelial Cell Count MeasurmentEndothelial Cell Count Change4 years-4 % change compared to baseline
Endothelial Cell Count MeasurmentEndothelial Cell Count Change5 years-1 % change compared to baseline

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026